Tissue Regeneration Systems
Kirkland-based software company, TRS, pioneers in skeletal reconstruction and bone regeneration technology, awaiting FDA approval.
Founded
2005Kirkland-based software company, TRS, pioneers in skeletal reconstruction and bone regeneration technology, awaiting FDA approval.
Tissue Regeneration Systems (TRS) is a medical device startup founded to commercialize innovative skeletal reconstruction and bone regeneration technologies licensed from the Universities of Michigan and Wisconsin. The company's core mission is to revolutionize bone healing and skeletal reconstruction through its advanced technology platform. TRS has developed initial product offerings, completed comprehensive bench and animal testing, and submitted its first regulatory filings to the FDA, aiming to address significant unmet needs in orthopedic surgery and trauma care.
Notable individuals affiliated with TRS include leading researchers from the licensing universities and experienced professionals in medical device development. The company has garnered attention for its promising long-term results in large animal studies, positioning itself as a potential game-changer in the field of bone regeneration. With its groundbreaking technology and strategic academic partnerships, TRS is poised to make a substantial impact on improving patient outcomes in skeletal reconstruction.
Companies similar to Tissue Regeneration Systems include Tissue Regeneration, Tissue Genesis, BioTissue and Molecular Matrix.
Tissue Regeneration Systems was founded in 2005.
Tissue Regeneration Systems' headquarters is located in Kirkland, WA, US.
Tissue Regeneration Systems' most recent funding round was for $4.1M (USD) in May 2015.
As of May 19, 2015, Tissue Regeneration Systems has raised a total of $18.3M (USD).
Tissue Regeneration Systems has 30 employees as of Feb 4, 2024.
BioTissue
biotissue.com
